Journal article
A Distinct Advantage to Intraarterial Delivery of 89Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood–Brain Barrier
Abstract
Glioblastoma multiforme (GBM) is the most aggressive and common type of brain cancer. Five-year survival rates are below 12%, even with the most aggressive trimodal therapies. Poor blood-brain barrier (BBB) permeability of therapeutics is a major obstacle to efficacy. Intravenous administration of bevacizumab is the standard treatment for GBM. It has been recently demonstrated that a single intraarterial infusion of bevacizumab provides …
Authors
Lesniak WG; Chu C; Jablonska A; Du Y; Pomper MG; Walczak P; Janowski M
Journal
Journal of Nuclear Medicine, Vol. 60, No. 5, pp. 617–622
Publisher
Society of Nuclear Medicine
Publication Date
May 2019
DOI
10.2967/jnumed.118.218792
ISSN
0161-5505